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S U M M A R Y
Background: Group B Streptococcus (GBS) is an important neonatal pathogen associated with high
morbidity and mortality in developed countries. However, data describing neonatal GBS disease in
developing countries, particularly in Asia, are largely incomplete. The aim of this study was to determine
the serotype distribution, antimicrobial resistance, and molecular characteristics of invasive GBS isolates
recovered from Chinese neonates.
Methods: From 2008 to 2013, 40 GBS isolates were recovered from infected neonates less than 3 months
of age. All isolates were identiﬁed with the CAMP test and commercially available techniques. Serotyping
was performed by latex agglutination. Antibiotic susceptibility was tested with Etest strips and the disk
diffusion method. Multilocus sequence typing and erythromycin resistance gene detection (ermB and
mefA) were performed by PCR.
Results: Four serotypes were identiﬁed. Serotype III (85%) was the most prevalent, followed by Ia (7.5%),
Ib (5%), and V (2.5%). All isolates were sensitive to penicillin, ceftriaxone, and levoﬂoxacin. However,
resistance to erythromycin (92.5%), clindamycin (87.5%), and tetracycline (100%) was observed. Among
erythromycin-resistant isolates, 73.0% carried the ermB gene alone, 5.4% carried the mefA gene alone, and
21.6% expressed both ermB and mefA genes. A total of seven sequence types (STs) were identiﬁed; the
most prevalent was ST17, accounting for 80% of all isolates. Further, serotype III isolates contained ST17
(94.2%), ST19 (2.9%), and ST650 (2.9%).
Conclusion: Serotype distribution, antimicrobial susceptibility, and sequence type characterization in
Asia and in other global regions may contribute to improve the prevention and treatment of neonatal
GBS infections.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Group B Streptococcus (GBS), also known as Streptococcus
agalactiae, is a Gram-positive bacterium that is a leading causative
pathogen of severe and invasive neonatal infections such as
meningitis and sepsis, which are often associated with high
morbidity and mortality. In neonates, a GBS infection occurs as one
of two distinct types. Early-onset disease (EOD) is characterized by
the onset of symptoms during the ﬁrst week of life (0–6 days),
while late-onset disease (LOD) is characterized by the onset of
symptoms up to 3 months of age (7–89 days).1 An invasive GBSciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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as blood or cerebrospinal ﬂuid (CSF), or, less commonly, joint,
pleural, or pericardial ﬂuid.2
Serotype distribution is critical to understanding the epidemi-
ology of GBS infections. Currently, a total of 10 distinct GBS
serotypes (Ia, Ib, and II–IX) have been characterized according to
the capsular polysaccharide (CPS), one of the major known
virulence factors underlying invasive GBS disease.3 The most
common serotypes, Ia, Ib, II, III, and V, account for more than 85% of
serotypes in global regions that have reported serotype data,
including the Americas (96%), Europe (93%), and the Western
Paciﬁc (89%).4 A substantial proportion of EOD isolates and the
majority of LOD isolates are serotype III; this serotype is largely
responsible for invasive GBS disease.5
Recently, the incidence of neonatal GBS EOD in Australia, New
Zealand, and the USA has decreased putatively because of the
implementation of intrapartum antibiotic prophylaxis (IAP).6,7 In
developing countries such as China, however, neonatal GBS disease
remains problematic and has not been addressed adequately. Only
a few cases have been reported.
Widespread IAP may be disadvantageous to both mother and
child as it can cause anaphylaxis and/or contribute to the
development of antibiotic-resistant strains. To address these
concerns, vaccination of pregnant women remains an attractive
prospect for the prevention and treatment of GBS infections. To
provide a basis for the application of effective clinical antimicrobial
agents and the development of a GBS vaccine, the serotype
distribution, antibiotic susceptibility proﬁles, and molecular
features of invasive GBS isolates recovered from a cohort of
neonates in mainland China were examined.
2. Methods
2.1. Bacterial strains and serotype identiﬁcation
Forty non-redundant, invasive GBS isolates collected from
2008 to 2013 were analyzed in this study. These included
36 isolates recovered from neonates at Shenzhen Children’s
Hospital (Shenzhen, China) and four isolates recovered from
neonates at Beijing Obstetrics and Gynecology Hospital (Beijing,
China). Bacteria were cultured on sheep blood plates and
conﬁrmed by CAMP test and a commercially available streptococ-
cal grouping kit according to the methods described by Wang
et al.8 Serotype identiﬁcation was performed with a latex
agglutination kit (Statens Serum Institute, Denmark) as described
previously.9 This study protocol was in accordance with the ethical
standards of the responsible regional committee on human
experimentation and the Declaration of Helsinki of 1975 (revised
in 1983). It was approved by the ethics committees at Shenzhen
Children’s Hospital and Beijing Obstetrics and Gynecology Hospi-
tal. Informed written consent was obtained from the care providers
of all neonates enrolled in this study.
2.2. Antimicrobial susceptibility tests
The minimum inhibitory concentrations (MICs) of penicillin,
ceftriaxone, erythromycin, clindamycin, clarithromycin, levoﬂox-
acin, and azithromycin were determined using Etest strips (AB
Biodisk, Sweden). Susceptibilities to telithromycin and tetracycline
were determined by disk diffusion method (Oxoid). The break-
points adopted were in accordance with the 2012 criteria set by the
Clinical and Laboratory Standards Institute (CLSI). The breakpoint
for telithromycin was determined by comparison with the quality
control culture Streptococcus pneumoniae ATCC 49619. GBS isolates
were considered multidrug-resistant if they were not susceptible
to three or more classes of antimicrobials tested in this study.All antibiotic susceptibility data were analyzed using WHONET
5.6 software, as recommended by the World Health Organization
(WHO).
2.3. Detection of erythromycin resistance genes
Chromosomal DNA was extracted from overnight cultures of
GBS isolates grown on sheep blood agar plates containing 5%
deﬁbrinated sheep blood using a DNA Mini Kit (SBS Genetech,
China). PCR was used to detect the erythromycin resistance genes
ermB and mefA in all erythromycin-resistant GBS isolates using
primers and reaction conditions described previously.10 A total of
5 ml each PCR product was analyzed by electrophoresis on a 1.5%
agarose gel, stained with gold view (SBS, Beijing, China), and
visualized by UV transillumination.
2.4. Multilocus sequence typing (MLST)
MLST analyses were based on the ampliﬁcation and sequencing
of internal fragments within seven housekeeping genes (adhP,
pheS, atr, glnA, sdhA, glcK, and tkt). Primer pairs corresponding to
these genes were designed as described previously.11 Sequencing
results were submitted to the GBS MLST website (http://pubmlst.
org/sagalactiae/) to allow for allelic assignment and to determine
sequence type (ST).
3. Results
The collection for this study comprised 40 GBS isolates
recovered from 40 different neonatal patients with invasive
infections. Of these, 10 neonates were diagnosed with EOD and
were symptomatic within the ﬁrst week after birth (0–6 days),
while 30 neonates were diagnosed with LOD and were
symptomatic between 7 and 89 days after birth. The majority
of these GBS infection diagnoses were sepsis, pneumonia, and
meningitis.
3.1. Serotype distribution
A total of four serotypes were identiﬁed in this study. Overall,
the predominant serotype was III, accounting for 85% of all isolates,
followed by Ia (7.5%), Ib (5%), and V (2.5%). A signiﬁcantly greater
proportion of serotype III isolates was observed in neonates with
LOD (94%) when compared to those with EOD (60%). The other
identiﬁed serotypes (Ia, Ib, and V) were more likely to cause EOD.
Three different serotypes were identiﬁed in the 36 isolates
recovered at Shenzhen Children’s Hospital: 33 isolates were
serotype III, two isolates were serotype Ib, and one isolate was
serotype Ia. The distribution of isolates recovered from Beijing
Obstetrics and Gynecology Hospital was as follows: two isolates
were serotype Ia, one isolate was serotype III, and one isolate was
serotype V.
3.2. Antimicrobial susceptibility
The antimicrobial susceptibility and MIC results for nine
antimicrobial agents tested against all 40 GBS isolates are
presented in Table 1. All isolates were susceptible to penicillin,
ceftriaxone, levoﬂoxacin, and telithromycin; and all were resis-
tant to tetracycline. In contrast, 95%, 90%, 97.5%, and 100% of the
40 GBS isolates were non-susceptible to erythromycin, clinda-
mycin, clarithromycin, and azithromycin, respectively. Approxi-
mately 90% (36/40) were multidrug-resistant, and these isolates
exhibited co-resistance to erythromycin, clindamycin, and
tetracycline.
Table 1
Antimicrobial susceptibility and MICs of group B Streptococcus isolates
Antimicrobials Susceptibility MICa
S (%) I (%) R (%) MIC50
(mg/l)
MIC90
(mg/l)
Range (mg/l)
Penicillin 100 0 0 0.064 0.094 0.032–0.125
Ceftriaxone 100 0 0 0.125 0.19 0.047–0.5
Erythromycin 5 2.5 92.5 256 256 0.125–256
Clindamycin 10 2.5 87.5 64 256 0.094–256
Clarithromycin 2.5 5 92.5 256 256 0.25–256
Levoﬂoxacin 100 0 0 1 1.5 0.5–2
Azithromycin 0 2.5 97.5 256 256 1–256
Telithromycin 100% 0 0 -b - b - b
Tetracycline 0 0 100 - b - b - b
MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R,
resistant.
a MIC50, minimum inhibitory concentration at which 50% of isolates were
inhibited; MIC90, minimum inhibitory concentration at which 90% of isolates were
inhibited; MIC range, range of minimum inhibitory concentration.
b No data available for the disk diffusion test.
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A total of 37 isolates were resistant to erythromycin. Of these,
27 (73.0%) harbored the ermB gene alone, two (5.4%) isolates
harbored the mefA gene alone, and eight (21.6%) isolates harbored
both ermB and mefA.
3.4. MLST
MLST analyses revealed seven different STs among the 40 GBS
isolates. ST17 was the predominant ST; this accounted for 80% of
all isolates. ST650 represents a new ST identiﬁed in this study.
Relationships between STs and GBS serotypes of the 40 isolates
characterized in this study are presented in Table 2. A correlation
between serotype III and ST17 was evident, as ST17 accounted for
94.1% of all serotype III isolates. The other two serotype III isolates
belonged to ST19 and ST650.
4. Discussion
Reported data on invasive neonatal GBS infections in Asia are
sparse. To address this knowledge gap, a study that examined
serotype distribution, antimicrobial resistance, and molecular
characterization of invasive GBS isolates recovered from neonatal
patients at two different hospitals situated in mainland China was
performed.
In this study, it was found that neonatal GBS infections were
most commonly caused by serotypes III and Ia, and this ﬁndingTable 2
Relationships between sequence type and serotype in group B Streptococcus
isolates
Sequence type Serotype
III (%) Ia (%) Ib (%) V (%) Total (%)
ST17 32 0 0 0 32 (80)
ST23 0 2 0 0 2 (5)
ST12 0 0 2 0 2 (5)
ST24 0 1 0 0 1 (2.5)
ST19 1 0 0 0 1 (2.5)
ST1 0 0 0 1 1 (2.5)
ST650 1 0 0 0 1 (2.5)
Total (%) 34 (85) 3 (7.5) 2 (5) 1 (2.5) 40 (100)
ST, sequence type.concurs with a previous report from the USA.12 However, the data
differ from the results of a previous study comprising 1500 preg-
nant Chinese women that was performed in the 1990s, wherein
the reported serotype distribution was 36% serotype II, 26%
serotype III, and 18% serotype Ia, and neonates born from this
cohort were colonized with a serotype distribution of 13.5% Ia,
9.5% II, 11.5% III, and 57% NT (non-typeable).13–16 Additionally, it
was found in the present study that serotype III and Ia isolates
were responsible for 60% and 10% of EOD, as well as 94% and 3%
of LOD, respectively. These results differ from those of a previous
report from France in which serotypes III and Ia were recovered
in 54% and 24% of EOD, and 82% and 7% of LOD, respectively.17 It
is hypothesized that serotypes responsible for GBS infection
differ globally, and that these serotypes may vary over time.
Therefore, active investigation of serotype distribution in China
and Asia, as well as other global regions, should precede vaccine
development.
A retrospective study was performed of 200 children with
fatal neonatal pneumonia who died between 1953 and 2004,
with 34 fatal neonatal cases without any infectious disease
serving as a control group. Parafﬁn-embedded lung tissues were
collected for total genomic DNA extraction, and PCR and
Southern blot analyses were used for GBS detection and
molecular serotyping. It was demonstrated that the positive
GBS rate of the pneumonia group was signiﬁcantly higher than
that of the control group (PCR: 26% vs. 3% (p < 0 .01); Southern
blot: 65% vs. 18% (p < 0.01)). The positive rate in neonates
aged younger than 7 days was signiﬁcantly higher than that
in neonates aged older than 7 days in the pneumonia group.
The isolates of 22 GBS-positive neonates were serotypeable.
Of these, seven were identiﬁed as serotype Ia, six isolates
were serotype III, ﬁve were serotype II, and one was serotype
Ib.18 These results suggest that GBS is an important pathogen in
fatal neonatal pneumonia in China, particularly in EOD.
No further data on this phenomenon appear to have been
reported.
In this study, all isolates were susceptible to penicillin and
ceftriaxone. These data suggest that penicillin should be the ﬁrst
choice for antibiotic prophylaxis and treatment of GBS infections,
as recommended previously.19 Notably, the MIC of penicillin in
50% of strains was 0.094 mg/l, which is higher than the maximum
MIC (0.06 mg/l) reported in a previous study by this group.20 GBS
isolates with reduced penicillin susceptibility have also been
reported in Japan21 and Hong Kong.22 Further, all GBS isolates
tested in this study were sensitive to levoﬂoxacin; however,
ﬂuoroquinolone-resistant GBS clinical isolates, mainly belonging
to serotype III/ST19, have been reported previously.23 The
incidence of erythromycin resistance was 92.5%. This is higher
when compared to Taiwan (58.3%) and Western countries, with
reported resistance ranging from 11.5% to 32%.24–27 Last, the non-
susceptible rate to clindamycin reported here is higher than that in
Korea (54.0%)28 and the USA (38.4%).29
MLST allowed for the comparison of genetic proﬁles of isolates
recovered from various geographic areas. In the present study,
ST17 was most prevalent – as high as 80.0%. Interestingly, it has
been suggested previously that ST17 isolates have unique
characteristics independent of cps type that contribute to more
invasive disease.30
In summary, the data from this study provide important
epidemiological information on invasive GBS isolates recovered
from neonates in China. The most prevalent serotype III /ST17
clone exhibited increased resistance to clindamycin and erythro-
mycin. This study contributes to the basic knowledge required for
successful GBS vaccine development suited for disease prevention
and treatment in China, as well as the implementation of effective
clinical antimicrobials.
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